Evidence map›Paper›PMID 32775597›Full record

ReviewAlzheimer's & dementia (Amsterdam, Netherlands)2020

The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology.

Benjamin L Handen, Ira T Lott, Bradley T Christian, Nicole Schupf, Sid OBryant, Mark Mapstone, Anne M Fagan, Joseph H Lee, Dana Tudorascu, Mei-Cheng Wang and 13 more

Abstract readReview
In one paragraph

Review in Alzheimer's & dementia (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Age predicts Alzheimer's in Down syndrome better than MRI, plasma, or cognition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  7. Structural MRI across lifespan reveals differential thalamic trajectories in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Adaptive and Maladaptive Behaviours and Their Cognitive Correlates in Aging Adults With Down Syndrome.Journal of applied research in intellectual disabilities : JARID · 2026
    Article
  12. The forgotten population: Early-onset Alzheimer's in people with Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  13. Article
  14. Article
  15. Novel insights into Alzheimer's disease through the study of individuals with Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Examination of metabolic syndrome in Down syndrome and association with dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Benjamin L HandenDepartment of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA.
Ira T LottIrvine School of Medicine Department of Pediatrics University of California Orange California USA.
Bradley T ChristianWaisman Center University of Wisconsin Madison Madison Wisconsin USA.
Nicole SchupfTaub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University Irving Medical Center New York New York USA.
Sid OBryantDepartment of Pharmacology and Neuroscience and Institute for Translational Research University of North Texas Health Science Center Fort Worth Texas USA.
Mark MapstoneIrvine Department of Neurology University of California Irvine California USA.
Anne M FaganDepartment of Neurology Washington University in St. Louis St Louis Missouri USA.
Joseph H LeeDepartment of Neurology Center, Taub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University College of Physicians and Surgeons New York New York USA.
Dana TudorascuDepartment of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA.
Mei-Cheng WangJohns Hopkins Bloomberg School of Public Health Baltimore Maryland USA.
Elizabeth HeadIrvine Department of Pathology University of California Irvine California USA.
William KlunkDepartment of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA.
Beau AncesWashingston University School of Medicine in St. Louis St. Louis Missouri USA.
Florence LaiMassachusetts General Hospital Department of Neurology Harvard Medical School Charlestown Massachusetts USA.
Shahid ZamanSchool of Clinical Medicine Department of Psychiatry University of Cambridge Cambridge UK.
Sharon Krinsky-McHaleDepartment of Psychology NYS Institute for Basic Research in Developmental Disabilities Staten Island New York USA.
Adam M BrickmanDepartment of Neurology Center, Taub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University College of Physicians and Surgeons New York New York USA.
H Diana RosasMassachusetts General Hospital Departments of Neurology and Radiology Harvard Medical School Charlestown Massachusetts USA.
Annie CohenDepartment of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA.
Howard AndrewsTaub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University Irving Medical Center New York New York USA.
Sigan HartleyWaisman Center University of Wisconsin Madison Madison Wisconsin USA.
Wayne SilvermanIrvine School of Medicine Department of Pediatrics University of California Orange California USA.
Alzheimer's Biomarker Consortium‐Down Syndrome (ABC‐DS)

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Project 3: Biomarkers for DS Clinical TrialsU19AG068054 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANCES, BEAU M · 2020 to 2025
$103.7M
Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWEET, ROBERT A · 1985 to 2019
$43.0M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sanjay Asthana · 2019 to 2026
$34.5M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PHILIP L DE JAGER · 2020 to 2026
$30.1M
NCATS NIH HHS UL1 TR001414NCATS NIH HHS UL1 TR001857NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002345NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066507NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG008702NIA NIH HHS U01 AG051406NIA NIH HHS U01 AG051412NIA NIH HHS U19 AG068054NIA NIH HHS U24 AG021886NICHD NIH HHS U54 HD087011NICHD NIH HHS U54 HD090256
6 · The paper itself

Abstract

introductionAdults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments.

methodsWe describe the development of a multi-center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid-based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16-month intervals), as well as genetic modifiers of AD risk and progression.

resultsApproximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and statistical cores is provided. DISCUSSION: This represents the largest U.S.-based, multi-site, biomarker initiative of AD in DS. Findings can inform other multidisciplinary networks studying AD in the general population.

Indexed as

ABC‐DSAlzheimer's diseasedementiaDown syndrome

Identifiers

PMID32775597
PMCPMC7396809

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.